Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?

GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research • Aug 19, 2026

GeneDx: Why I Think The Worst Is Behind The Business

GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.

Seeking Alpha • Aug 18, 2026

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.

Business Wire • Aug 11, 2026

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.

Business Wire • Aug 6, 2026

Alger Small Cap Focus Fund Q2 2026 Portfolio Review

Nebius Group, Credo Technology Group, and Guardant Health, Inc. were among the top contributors to performance. During the quarter, Credo shares contributed positively to performance as investors responded favorably to the company's rapid revenue growth and rising demand from hyperscale customers. Karman Holdings Inc., GeneDx Holdings Corp., and Forte Biosciences Inc. were among the top detractors from performance.

Seeking Alpha • Aug 6, 2026

GeneDx Q2 Earnings Call Highlights

GeneDx NASDAQ: WGS reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintaining its full-year 2026 outlook.

MarketBeat • Aug 3, 2026

GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript

GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

DEADLINE TODAY: GeneDx Holdings Corp. Investor Alert: Contact SBS by August 3, 2026 for Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. If you purchased GeneDx Holdings Corp. securities during the Class Period you may be entitled to compensation without payment of any out-of-pocket fees or costs.

PRNewsWire • Aug 3, 2026

GeneDx Reports Second Quarter 2026 Financial Results

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.

Business Wire • Aug 3, 2026

WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. (“GeneDx” or “the Company”) (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

GlobeNewsWire • Aug 3, 2026